4 trends tracked about this subject — the full history, oldest to newest below.
Genentech has entered a global license agreement with Alector for a preclinical brain-penetrant enzyme replacement therapy targeting Parkinson's disease.
BioNTech and Genentech have terminated a phase 2 mRNA colorectal cancer vaccine trial after safety reviews revealed more deaths than in the control group.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.